|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications显示文摘AIM: The significance of preoperative serum IL-6, TNFαand CRP levels in the progression of colorectal cancer (CRC) has not been fully elucidated. Our intention was to investigate their role and identify their prognostic significance.METHODS: The IL-6, TNFα and CRP levels were measured in 74 CRC patients and the relationships between their elevation s and both the clinicopathological factors and prognosis of patients were investigated. Serum concentrations of human IL-6 and TNFα were determined by enzyme-linked immunosorbent assay (ELISA). CRP was measured by an immunoturbinometric method.RESULTS: Median IL-6, TNFα and CRP levels weresignificantly higher in CRC patients than in normal controls.High levels of serum IL-6, TNFα and CRP were correlated with larger tumor size. Furthermore, high IL-6 and high CRP levels were associated with reduced overall survival.CONCLUSION: Serum IL-6, TNFα and CRP levels definitely increase in CRC patients. Pre-operative serum elevation of IL-6 and CRP was thus found to be predictor of the prognosis of CRC patients. The clinical value of TNFα in CRC needs to be further investigated. | Nikolaos I. Nikiteas Nikolaos Tzanakis Maria Gazouli George Rallis Kessaris Daniilidis George Theodoropoulos Alkiviadis Kostakis George Peros | 2005 | World Journal of Gastroenterology2005，11，11： | 23 |
| 2 | Pulmonary involvement and allergic disorders in inflammatory bowel disease显示文摘Inflammatory bowel disease (IBD) has been associated with either clinical or subclinical airway and parenchymal lung involvement and interstitial lung complications. Several studies have reported that atopy has a high prevalence in IBD patients. Overlapping allergic disorders seem to be present in both the respiratory and gastrointestinal systems. The purpose of this review is to update clinicians on recent available literature and to discuss the need for a highly suspicious approach by clinicians. | Nikolaos E Tzanakis Ioanna G Tsiligianni Nikolaos M Siafakas | 2010 | World Journal of Gastroenterology2010，16，3： | 11 |
| 3 | Is there a role of lipid-lowering therapies in the management of fatty liver disease?显示文摘Atherogenic dyslipidemia is characterized by increased triglyceride-rich lipoproteins and low high-density lipoprotein cholesterol concentrations.It is highly prevalent in non-alcoholic fatty liver disease(NAFLD)and contributes to the increased cardiovascular risk associated with this condition.Alongside insulin resistance it plays an important pathogenetic role in NAFLD/non-alcoholic steatohepatitis(NASH)development and progression.It has been shown that cholesterol-lowering reduces cardiovascular risk more in NAFLD vs non-NAFLD high-risk individuals.This evidence highlights the importance of effective lipid modulation in NAFLD.In this narrative review the effects of the most commonly used lipid-lowering therapies on liver outcomes alongside their therapeutic implications in NAFLD/NASH are critically discussed.Preclinical and clinical evidence suggests that statins reduce hepatic steatosis,inflammation and fibrosis in patients with NAFLD/NASH.Most data are derived from observational and small prospective clinical studies using changes in liver enzyme activities,steatosis/fibrosis scores,and imaging evidence of steatosis as surrogates.Also,relevant histologic benefits were noted in small biopsy studies.Atorvastatin and rosuvastatin showed greater benefits,whereas data for other statins are scarce and sometimes conflicting.Similar studies to those of statins showed efficacy of ezetimibe against hepatic steatosis.However,no significant anti-inflammatory and anti-fibrotic actions of ezetimibe have been shown.Preclinical studies showed that fibrates through peroxisome proliferator-activated receptor(PPAR)αactivation may have a role in NAFLD prevention and management.Nevertheless,no relevant benefits have been noted in human studies.Species-related differences in PPARαexpression and its activation responsiveness may help explain this discrepancy.Omega-3 fatty acids reduced hepatic steatosis in numerous heterogeneous studies,but their benefits on hepatic inflammation and fibrosis have not been established.Promising preliminary data for the highly purified eicosapentaenoic acid require further confirmation.Observational studies suggest that proprotein convertase subtilisin/kexin9 inhibitors may also have a role in the management of NAFLD,though this needs to be established by future prospective studies. | Ismini Tzanaki Aris P Agouridis Michael S Kostapanos | 2022 | World Journal of Hepatology2022，14，1： | 2 |
| 4 | Prostate-spe cific antigen in hemodialysis patients and the influence of dialysis in its leve/显示文摘 | TZANAKIS I KAZOULIS S GIROUSIS N | 2002 | Nephron2002，90，23： | 1 |
| 5 | Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease显示文摘 | Tsoumakidou M Tzanakis N Chrysofakis G | 2005 | Respir Med2005，99，5： | 1 |
| 6 | Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-lb therapy in idiopathic pulmonary fibrosis patients显示文摘 | Antoniou KM Tzanakis N Tzortzaki EG | | 0，，06： | 1 |
| 7 | Prevalence of COPDin Greece显示文摘 | Tzanakis N Anagnostopou U Filaditaki V | 2004 | Chest2004，125，3： | 1 |
| 8 | Geoepidemiology and space–time analysis of Primary biliary cirrhosis in Crete, Greece显示文摘 | M Koulentaki A Mantaka D Sifaki‐Pistolla E Thalassinos N Tzanakis E Kouroumalis | 2014 | Liver Int2014，，7： | 1 |
| 9 | Diagnostic value of in- terleukin-I ,interleukin-6, and tumor necrosis factor in pleural ef- fusions显示文摘 | Xirouchaki N Tzanakis N Boures D | 2002 | Chest2002，121，3： | 1 |
| 10 | Induced sputum CD8 + T-lymphocyte subpopulations in chronic obstructive pulmonary disease显示文摘 | Tzanakis N Chrysofakis G Tsoumakidou M | 2004 | Respir Med2004，98，1： | 1 |
| 11 | Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis显示文摘 | Tzortzaki EG Antoniou KM Zervou MI Lambiri I Koutsopoulos A Tzanakis N Plataki M Maltezakis G Bouros D Siafakas NM | 2007 | Respir Med2007，101，8： | 1 |
| 12 | Experimental and analytical thermal study of PTFE composite sliding against high carbon steel as a function of the surface roughness,sliding velocity and applied load显示文摘 | TZANAKIS I CONTE M HADFIELD M | 2013 | Wear2013，303，1： | 1 |
| 13 | Contribution of Psychological Factors in Dropping out from Chronic Obstructive Pulmonary Disease Rehabilitation Programs显示文摘 | Athanasios Tselebis Epaminondas Kosmas Dionisios Bratis Argiro Pachi Ioannis Ilias Maria Harikiopoulou Elpida Theodorakopoulou Konstantinos Velentzas Silvia Dumitru Georgios Moussas Nikolaos Siafakas Nikolaos Tzanakis Mitja Lainscak | 2014 | BioMed Research International2014，，： | 1 |
| 14 | Prevalence of COPD in Greece显示文摘 | Tzanakis N Anagnostopoulou U Filaditaki V | | 0，，03： | 1 |
| 15 | Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population显示文摘 | Panagiotis Dikeakos George Theodoropoulos Spyros Rizos Nikolaos Tzanakis George Zografos Maria Gazouli | 2014 | Molecular Biology Reports2014，，2： | 1 |
| 16 | Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease显示文摘 | Tzanakis N Chrysofakis G Tsoumakidou M | 2004 | Respir Med2004，98，1： | 1 |
| 17 | Spontaneous renal rupture due to ureteric calculi in a paraplegic male显示文摘 | Kazoulis S Tzanakis I Christoulakis I | 2002 | Nephron2002，91，4： | 1 |
| 18 | Perforin expression and cytotoxic activity of sputum CDs+ lymphocytes in patients with COPD显示文摘 | Chrysofakis G Tzanakis N Kyriakoy D | 2004 | Chest2004，125，： | 1 |
| 19 | Vascular endo?thelial growth factor and endoglin (CDI05) in gastric cancer显示文摘 | Nikiteas NI Tzanakis N Theodoropoulos G | 2007 | Gastric Cancer2007，10，1： | 1 |
| 20 | Altered surfactant protein-A expression in type II pneumocytes in COPD显示文摘 | Vlachaki EM Koutsopoulos AV Tzanakis N | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员